Brawn Biotech

Brawn Biotech Goodwill/Assets

Goodwill to Total Assets Ratio of Brawn Biotech (530207.BO) as of Oct 17, 2026.

Goodwill/Assets

0.00

Last updated:

Goodwill to Total Assets Ratio of Brawn Biotech is 2025 0.00 . Goodwill to Total Assets Ratio of Brawn Biotech was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brawn Biotech Stock analysis

What does Brawn Biotech do? Brawn Biotech Ltd, headquartered in New Delhi, India, operates in the Health Care sector, specializing in the manufacture, contracting, and supply of pharmaceutical and medical products. The company offers a comprehensive range of pharmaceutical products including antibacterials, cardiovasculars, antidiabetics, analgesics, gastrointestinals, antifungals, skin care, antipsychotics, antiasthmatics, antacids, antimalarials, and nutritionals. Its product portfolio includes Sefix-400 Capsules, Cefixime Tablets, and various other formulations for diverse medical needs. Brawn Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brawn Biotech stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Brawn Biotech since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Brawn Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Brawn Biotech

All Key Metrics — Brawn Biotech